Editorial: Clinical and molecular aspects of managing chronic urticaria: identifying endotypes, phenotypes, and factors determining responses and resistance to treatment. [PDF]
Front AllergySalman A +3 more
europepmc +1 more source
Advancements and challenges in the management of chronic inducible urticaria. [PDF]
Front ImmunolZhang M, Liu J, Zhi Y.
europepmc +1 more source
Cytokine imbalance and immune network endotypes underlying heterogeneous response to omalizumab in chronic spontaneous urticaria. [PDF]
Front ImmunolYe YM +5 more
europepmc +1 more source
Neoplasm Adverse Events Associated With Anti-Type 2 Biologics: An FAERS Database Pharmacovigilance Analysis Study. [PDF]
Cancer MedLyu W +9 more
europepmc +1 more source
Oral Food Challenges After Treatment With Omalizumab in the Clinical Setting. [PDF]
J Allergy Clin Immunol PractTseng H +4 more
europepmc +1 more source
Comparative efficacy and safety of biologic therapies in pediatric asthma: a comprehensive systematic review. [PDF]
Front Med (Lausanne)Alzayed A.
europepmc +1 more source
Eosinophilic Granulomatous Polyangiitis Emerging After Omalizumab Administration: An Asthma Patient Without Systemic Corticosteroids Develops Mononeuritis Multiplex After 22 Days. [PDF]
Eur J RheumatolWang Z, Lin S, Yang J, Cheng M, Cai M.
europepmc +1 more source
Targeting immune dysregulation in chronic spontaneous urticaria: beyond antihistamines. [PDF]
Korean J Intern MedYe YM.
europepmc +1 more source
Novelties in the pragmatic management of anaphylaxis in pediatric age. [PDF]
Eur J PediatrMarseglia GL +5 more
europepmc +1 more source
Safety and efficacy of omalizumab in children aged 6 to 11 years with asthma: a systematic review and meta-analysis of randomized controlled trials. [PDF]
BMC PediatrYang Y, Fang C, Jiang Z, Su X, Fan W.
europepmc +1 more source